Valeant Pharmaceuticals is on
the acquisition trail again, overnight
announcing a deal to purchase
precision optical surgical device
supplier Synergetics USA.
The definitive agreement, worth
more than US$160 million, aims
to increase the global presence of
Valeant’s Bausch & Lomb offshoot
in “the rapidly evolving field of
vitreoretinal surgery,” according to
Valeant ceo J. Michael Pearson.
The board of Synergetics has
unanimously approved the
deal which includes an up-front
payment of US$6.50 per share, plus
milestone payments.
Other recent Valeant acquisitions
include Sprout Pharmaceuticals.The above article was sent to subscribers in Pharmacy Daily's issue from 03 Sep 15 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 03 Sep 15
MONTU Group, its subsidiary Alternaleaf Pty Ltd, and their common director Christopher Strauch are facing legal action by the Therapeutic Goods Administration (TGA) in the Federal Court of Australia for alleged unlawful advertising on the effectiveness of their medicinal cannabis products.
AUSTRALIA’S public hospitals are facing their lengthiest wait times on record for planned surgeries, with emergency departments struggling under access blockages, according to the latest annual Public Hospital Report Card by the Australian Medical Association (AMA).
THE University of South Australia has released a new study to help healthcare workers better support women with persistent pelvic pain, including symptoms that are suggestive of gynaecological, lower urinary tract, bowel, sexual, and pelvic floor dysfunction.
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.